Relapsed/refractory ovarian carcinoma

Clinical trials for Relapsed/refractory ovarian carcinoma explained in plain language.

Never miss a new study

Get alerted when new Relapsed/refractory ovarian carcinoma trials appear

Sign up with your email to follow new studies for Relapsed/refractory ovarian carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New Immune-Engaging drug takes aim at Hard-to-Treat ovarian cancer

Disease control Recruiting now

This early-stage trial tests an investigational drug called NTB-928 in women with ovarian cancer that has come back or no longer responds to standard treatments. NTB-928 is designed to direct the body's immune T cells to attack cancer cells by targeting a protein called FRα. The …

Matched conditions: RELAPSED/REFRACTORY OVARIAN CARCINOMA

Phase 1 • Sponsor: TeneoSeven, Inc. • Aim: Disease control

Last updated Aug 22, 2026 00:00 UTC

Relapsed/refractory ovarian carcinoma

Get alerted when new Relapsed/refractory ovarian carcinoma trials appear

New Immune-Engaging drug takes aim at Hard-to-Treat ovarian cancer